18 assets in Phenylketonuria

Therapeutic assets addressing Phenylketonuria, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Sapropterin Dihydrochloride Phenylketonuria	Sohag University	P4	A (82)
Phenylase Phenylketonuria	BioMarin Pharmaceutical	P4	A (81)
Repinatrabit Phenylketonuria	Otsuka Pharmaceutical Development & Commercialization, Inc.	P3	BB (68)
L-Carnitine Phenylketonuria	Mansoura University	P4	BB (65)
Sepiapterin Phenylketonuria	PTC Therapeutics	P3	B (62)
Methotrexate Phenylketonuria	BioMarin Pharmaceutical	P4	B (59)
Synb1934V1 Phenylketonuria	Synlogic	P3	B (57)
Nggt002 Phenylketonuria	NGGT INC.	P1/2	CCC (54)
Dna (Recombinant Human Hematopoietic Stem Cell-Derived Adeno-Associated Virus Vector Serotype Aavhsc15 Human Liver-Specific Expression Cassette Including Human Phenylalanine 4-Hydroxylase Codon-Optimized Cdna Plus Adeno-Associated Virus 2 Inverted Terminal Repeat Flanks) Phenylketonuria	Homology Medicines, Inc	P1/2	CC (47)
Dna (Recombinant Replication-Deficient Adeno-Associated Virus 5 Vector Bmn 307 Human Liver-Specific Transcription Regulatory Element Plus Human Phenylalanine 4-Hydroxylase Codon-Optimized Gene Hpah Plus Adeno-Associated Virus 2 Inverted Terminal Repeat Flanks) Phenylketonuria	BioMarin Pharmaceutical	P1/2	CC (47)
Mrna-3210 Phenylketonuria	ModernaTX, Inc.	P1/2	CC (47)
sar444836 Phenylketonuria	Sanofi	P1/2	CC (47)
ag-181 Phenylketonuria	Agios Pharmaceuticals, Inc.	P1	CC (43)
cbt102-a Phenylketonuria	Children's Hospital of Fudan University	Early P1	CC (43)
Hmi-103 Phenylketonuria	Homology Medicines, Inc	P1	CC (43)
PL54 Phenylketonuria	Chongqing Peg-Bio Biopharm Co., Ltd.	P1	CC (43)
gs1168 Phenylketonuria	Gritgen Therapeutics Co., Ltd.	Early P1	NR ()